Aura Biosciences is a clinical-stage oncology company developing virus-like drug conjugates (VDCs), a novel targeted therapy platform, with lead candidate bel-sar in development for early-stage choroidal melanoma (a rare eye cancer with no approved treatments) and expansion into choroidal metastasis and bladder cancer.